China included SSY's (HKG:2005) stiripentol dry suspension and its etomidate medium/long chain fat emulsion injection in its insurance reimbursement drug catalog, according to a Monday filing with the Hong Kong Exchange.
Stiripentol is indicated for the treatment of myoclonic epilepsy in children, while etomidate is for general anesthesia induction, the filing said.
Shares jumped 1% during Monday's afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments